AstraZeneca Investor Day Presentation Deck
16
Conclusions
• TOPAZ-1 is the first global Phase III trial to report positive results testing immunotherapy
plus chemotherapy as first-line treatment for advanced BTC
TOPAZ-1 met its primary endpoint at the prespecified interim analysis: durvalumab plus
GemCis demonstrated statistically significant and clinically meaningful prolonged overall
survival compared with placebo plus GemCis
Durvalumab did not add additional toxicity to that observed with GemCis, and no new
safety signals were identified from the known safety profiles of each individual
treatment
Durvalumab plus GemCis is an effective first-line therapy, and could become a new
standard of care, for patients with advanced BTC
BTC, biliary tract cancer; GemCis, gemcitabine and cisplatin.View entire presentation